|
Dr Sassine has a successful track-record in this sector.
I'm
impressed with the number and scope of significant outcomes and activities VSG
have been able to achieve on the funds they've had available to them..I'm not
expecting any fireworks with the Qtrly report, but nor am I expecting anything
adverse. Lessons learnt - I think VSG will take pains to ensure the ASX are
totally satisfied (in advance) this quarter.
Recent Significant
Activities:
1) Funhaler: Co-development alliance on Funhaler with Pari
GmbH (leading worldwide manufacturer of delivery products for asthma, chronic
lung disease & cystic fibrosis - Germany, Japan, UK, Canada currently
involved in more clinical trials for new nebulizer respiratory medications than
all other brands combined, including trials by large pharma companies such as
Astra Zeneca and Separcor Inc). Co-development trial is for Funhaler to be
incorporated into Pari's delivery devices - VSG view is to sell or licence
Funhaler - co-development trial already funded under NIH $1M grant awarded to
VSG's collaborating asthma researchers at Univ of WA.
2) Microderm
nearing FDA approval - minor edits outstanding - expected by end financial year.
(The last thing I read on FDA stated that a high percentage of FDA committee are
specialist dermatologists.) FDA clearance will pave the way for sales of
Microderm in the US. Visiomed has initiated a search for suitable partners and
distributors in the US. VSG has already received an expession of interest from
one suitably positioned party. (NB Huge market - sadly, around 10,000 Americans
die from Melanoma every year.) European clinical studies have already commenced.
Visiomed has secured a number of Australian clinical sites for Aust studies to
support FDA approval. (NB Significantly; these studies are retrospective
not prospective = very short time frame.)
Price will catch up to the
vision and I am personally anticipating sooner rather than
later.
Regards,
Cris
----- Original Message -----
Sent: Tuesday, April 27, 2004 3:04
PM
Subject: Re: [sharechat] VSG Upside
Potential Looking Good.
Someone bought up big today:
Visiomed Group Limited (VSG)
Date Time Price
($) Quantity Value ($) Conditions
27-04-2004 02:51 PM $0.064 150000
$9,600.000
27-04-2004 02:29 PM $0.064 10000
$640.000
27-04-2004 02:29 PM $0.064 50000
$3,200.000
27-04-2004 01:56 PM $0.065 38180
$2,481.700
27-04-2004 12:42 PM $0.062
2107388 $130,658.056 Crossed
27-04-2004 12:29 PM $0.062
68500 $4,247.000
27-04-2004 12:26 PM $0.063 31500 $1,984.500
Crossed
27-04-2004 10:30 AM $0.063 8500 $535.500 Crossed
27-04-2004
10:23 AM $0.063 91500 $5,764.500
26-04-2004 03:40 PM $0.064
100000 $6,400.000
----- Original Message -----
Sent: Tuesday, April 27, 2004 1:57
PM
Subject: Re: [sharechat] VSG Upside
Potential Looking Good.
ASX: VSG - Update lodged with ASX today at
12.38pm
| VSG |
12:38 PM |
|
On track for FDA Clearance
of Microderm Submission |
----- Original Message -----
Sent: Tuesday, April 20, 2004 3:53
PM
Subject: Re: [sharechat] VSG Upside
Potential Looking Good.
I have asked Visiomed when shareholders can expect
an update.
Visiomed will be posting out a newsletter to
shareholders in the near future.
----- Original Message -----
Sent: Monday, April 19, 2004 7:53
AM
Subject: Re: [sharechat] VSG Upside
Potential Looking Good.
FDA application has been lodged - approval
was anticipated around late April.
Everyone here knows my thoughts on this
one.
My expert TA analysis - higher highs,
higher lows and poised for another upturn especially in consideration of
anticipated FDA approval.
----- Original Message -----
Sent: Monday, April 19, 2004 5:46
AM
Subject: [sharechat] VSG Upside
Potential Looking Good.
Latest April 04 Aegis Equities Comments.
Through
the acquisition of Visiomed AG, VSG has not only secured full
control over the microDERM device but also has rights to any other
IP
developed within the German company. This includes some
interesting surgical
navigation technology that VSG may be able to
commercialise in the future.
The Funhaler provides a potential
spinout product that can help fund VSG's
other
ventures.
VSG has managed to build its patent portfolio over
the last year, an
important first step to eventual
commercialisation. A recent study was
published in the influential
British Journal of Dermatology detailing the
diagnostic use of the
MicroDERM system and this should help it achieve US
regulatory
approval as higher value diagnostic device. VSG also forged
closer
links with Siemens AG, one of the world's largest and most recognised
engineering and medical imaging companies, announcing an exclusive
Australian dealership for a range of Siemens medical imaging
systems. VSG is
also a significant participating collaborator with
Siemens in the
development of ultrasound-based surgical navigation
systems for spinal
procedures.
Lazy
Haggis
_________________________________________________________________
Watch
LIVE baseball games on your computer with MLB.TV, included with MSN
Premium!
http://join.msn.com/?page=features/mlb&pgmarket=en-us/go/onm00200439ave/direct/01/
----------------------------------------------------------------------------
To
remove yourself from this list, please use the form at
http://www.sharechat.co.nz/chat/forum/
|
See IRG research reports
